Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P13798
UPID:
ACPH_HUMAN
Alternative names:
Acyl-peptide hydrolase; Acylaminoacyl-peptidase; Oxidized protein hydrolase
Alternative UPACC:
P13798; Q9BQ33; Q9P0Y2
Background:
The Acylamino-acid-releasing enzyme, also known as Acyl-peptide hydrolase, Acylaminoacyl-peptidase, and Oxidized protein hydrolase, plays a crucial role in protein metabolism. It catalyzes the hydrolysis of N-acetylated peptides, facilitating the breakdown of oxidized and glycated proteins. This enzyme's specificity for Ac-Ala, Ac-Met, and Ac-Ser underscores its selective nature in protein processing.
Therapeutic significance:
Understanding the role of Acylamino-acid-releasing enzyme could open doors to potential therapeutic strategies. Its involvement in the degradation of damaged proteins suggests a protective mechanism against protein aggregation disorders, highlighting its potential as a target in therapeutic interventions.